툴젠

199800KOSDAQView the 바이오 R&D sectorTheme Bio & healthcare

28,050KRWMarket close of 10/27 (Tue)

Up +0.72%+200KRWMarket close of 10/27 (Tue)

Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)29,800KRWUp +6.24%

Preliminary · replaced once official KRX data for the same date is published

Open: 28,100
High: 28,600
Low: 27,750
Day range: Day range low 27,750 high 28,600, open 28,100, close 28,050, previous close 27,850
Volume: 1×10K shares
: 271.14 million KRW 0.30× the 20-session average

Market close of 10/27 (Tue)

Where it sits in the 1-year range

0% of the way up from the lowest close in 1 year (252 sessions) · -79.7% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Data dateMost recent closing data10/27 (Tue)

Market close data of 2026-10-27

Points to check

Earningsto check-23.3B KRWOperating income over the last four quarters -23.3B KRW (loss)Operating income, 8 quarters
Recent filingsnot verifiedOutside filing data coverage, so not verified
Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified

The other 2 are within the usual range

Daily move+0.72%usual range
Trading value0.3×usual range

See the full check report

Key figures

: 274.2B KRW
: Not computed — loss-making, or the four quarters are incomplete
: 5.16×
: 9,774,629 shares
Trading value ratio: 0.30× the 20-session average0.3×

52-week closing rangeNow 28,050

27,850138,200

Financials filed 2026-05-14 · KRX·DART

Something to check

1 to check: operating loss

Earningsto checkQuarterly operating income bars (6); the four dark bars make up the sum-23.3B KRW
Recent filingsnot verifiedOutside filing data coverage, so not verified
Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
Daily moveusual range+0.72% on the reference date, placed against the usual ±2.77% band0.3×
Trading valueusual range0.30× the 20-session average0.3×
Data dateusual rangeMarket close data of 2026-10-27

Quarterly results · Q1 2026

Source: DART financials (Q4 derived as annual − three quarters) · Amended filing reflected

Revenue390.71 million KRWRevenue bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
+202.6%
vs. prior quarter
-3.3%
Operating income-4.6B KRWOperating income bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
Still a loss
vs. prior quarter
Still a loss
Operating margin-1,175.6%Operating margin bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
+2,394.4 pp
vs. prior quarter
+541.3 pp

Quarterly operating income trend

As of the latest official close · 2026-10-27Valuation filing date · 2026-05-14

2022Q2 -3.8B KRW2026Q1 -4.6B KRWQ4 values are derived as the annual figure minus Q1–Q3. The value table marks them in the Type column.

Same sector · 바이오 R&D

· 26 of 64 stocks up, preferred shares excluded · trading value 190.2B KRW

Same sector · top by trading value
Stock	20D	Change	Trading value
알테오젠	Close over the last 20 sessions -12.6%	Flat 0.00%	51.8B KRW
올릭스	Close over the last 20 sessions -11.8%	Down -5.72%	24.1B KRW
디앤디파마텍	Close over the last 20 sessions -8.3%	Up +0.37%	14.0B KRW
리가켐바이오	Close over the last 20 sessions -20.9%	Down -1.54%	12.1B KRW
페니트리움바이오	Close over the last 20 sessions -4.2%	Up +14.41%	9.8B KRW

Schedule

Next data 10/29 (Thu) after 08:50

Related news

All news

Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 82% of trading value, about 92% of market capitalisation. Coverage status →

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.